HomeCompareRGLXF vs ABBV

RGLXF vs ABBV: Dividend Comparison 2026

RGLXF yields 6.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGLXF wins by $40874.72M in total portfolio value
10 years
RGLXF
RGLXF
● Live price
6.90%
Share price
$41.00
Annual div
$2.83
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40874.82M
Annual income
$39,767,491,255.63
Full RGLXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RGLXF vs ABBV

📍 RGLXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLXF
Annual income on $10K today (after 15% tax)
$586.42/yr
After 10yr DRIP, annual income (after tax)
$33,802,367,567.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RGLXF beats the other by $33,802,346,511.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLXF + ABBV for your $10,000?

RGLXF: 50%ABBV: 50%
100% ABBV50/50100% RGLXF
Portfolio after 10yr
$20437.46M
Annual income
$19,883,758,013.69/yr
Blended yield
97.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RGLXF
No analyst data
Altman Z
2.2
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLXF buys
0
ABBV buys
0
No recent congressional trades found for RGLXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLXFABBV
Forward yield6.90%3.06%
Annual dividend / share$2.83$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$40874.82M$102.3K
Annual income after 10y$39,767,491,255.63$24,771.77
Total dividends collected$40798.69M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RGLXF vs ABBV ($10,000, DRIP)

YearRGLXF PortfolioRGLXF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,080$1,379.80$11,550$430.00+$530.00RGLXF
2$16,041$3,115.47$13,472$627.96+$2.6KRGLXF
3$24,897$7,732.82$15,906$926.08+$9.0KRGLXF
4$49,073$22,433.41$19,071$1,382.55+$30.0KRGLXF
5$135,158$82,649.96$23,302$2,095.81+$111.9KRGLXF
6$570,109$425,490.38$29,150$3,237.93+$541.0KRGLXF
7$3,964,712$3,354,694.86$37,536$5,121.41+$3.93MRGLXF
8$47,848,900$43,606,658.90$50,079$8,338.38+$47.80MRGLXF
9$1,034,890,872$983,692,548.76$69,753$14,065.80+$1034.82MRGLXF
10$40,874,824,489$39,767,491,255.63$102,337$24,771.77+$40874.72MRGLXF

RGLXF vs ABBV: Complete Analysis 2026

RGLXFStock

RTL Group S.A., an entertainment company, operates television (TV) channels and radio stations, and provides streaming services in Germany, France, the Netherlands, Belgium, the United Kingdom, the United States, and internationally. The RTL Deutschland segment operates RTL, Vox, Super RTL, Toggo Plus, NTV, Nitro, Vox Up, and RTL Up free-to-air channels; RTL Crime, RTL Passion, RTL Living, GEO Television, and Now! thematic pay channels; and RTL Zwei, an equity participation in the free-to-air channel. This segment also offers streaming service RTL+; engages in content activities, such as the production companies RTL Studios and RTL News; and provision of RTL Radio Deutschland and ad-tech business, Smartclip. The Groupe M6 segment operates television channels; radio stations; and digital services, including mobile applications and IPTV services. The Fremantle segment is involved in the content production comprising of distribution and licensing business. The RTL Nederland segment operates RTL 4, RTL 5, RTL 7, RTL 8, RTL Z, RTL Lounge, RTL Crime, and RTL Telekids TV channels; and Videoland, a pay streaming service, as well as offers RTL XL, a catch-up TV service in the Netherlands. The Other segment operates RTL play, a streaming service; RTL-TVI; RTL Klub; Club RTL; RTL Most, a streaming platform; RTL Televizija; RTL 2; RTL Kockica children's channels; RTL Luxembourg; RTL Radio Letzebuerg; and RTL Tele Letzebuerg, a general interest TV channel. The company was founded in 1924 and is based in Luxembourg City, Luxembourg. RTL Group S.A. is a subsidiary of Bertelsmann Capital Holding GmbH.

Full RGLXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RGLXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLXF vs SCHDRGLXF vs JEPIRGLXF vs ORGLXF vs KORGLXF vs MAINRGLXF vs JNJRGLXF vs MRKRGLXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.